Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Seladelpar Study in Primary Biliary Cholangitis
2017-003910-16Phase 3Terminated
- Sponsor
- CymaBay Therapeutics
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of seladelpar in primary biliary cholangitis (PBC), sponsored by CymaBay Therapeutics. Primary endpoint: Treatment Emergent Adverse Events. Started Nov 2017; status: terminated.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2017-003910-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003910-16.